Gene · 965
Papers4,043
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
681 to 700 of 4,043
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Allele-specific transcription factor binding in a cellular model of orofacial clefting. | Sci Rep | 2022 | 35110662 | PubTator, text mining | PubMed |
| An Efficient Gaussian-Accelerated Molecular Dynamics (GaMD) Multilevel Enhanced Sampling Strategy: Application to Polarizable Force Fields Simulations of Large Biological Systems. | J Chem Theory Comput | 2022 | 35080892 | PubTator, text mining | PubMed |
| Uncovering emergent phenotypes in endothelial cells by clustering of surrogates of cardiovascular risk factors. | Sci Rep | 2022 | 35079076 | PubTator, text mining | PubMed |
| NK cells in the brain: implications for brain tumor development and therapy. | Trends Mol Med | 2022 | 35078713 | PubTator, text mining | PubMed |
| CRISPR activation enables high-fidelity reprogramming into human pluripotent stem cells. | Stem Cell Reports | 2022 | 35063129 | PubTator, text mining | PubMed |
| Molecular Subgroups of Diffuse Large B Cell Lymphoma: Biology and Implications for Clinical Practice. | Curr Oncol Rep | 2022 | 35060000 | PubTator, text mining | PubMed |
| Challenges and Opportunities for the Translation of Single-Cell RNA Sequencing Technologies to Dermatology. | Life (Basel) | 2022 | 35054460 | PubTator, text mining | PubMed |
| Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia. | Cancers (Basel) | 2022 | 35053619 | PubTator, text mining | PubMed |
| Minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients. | J Ovarian Res | 2022 | 35042558 | PubTator, text mining | PubMed |
| Guidelines for standardizing T-cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes. | Eur J Immunol | 2022 | 35025103 | PubTator, text mining | PubMed |
| Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia. | Blood Cancer Discov | 2022 | 35019853 | PubTator, text mining | PubMed |
| The interplay between membrane topology and mechanical forces in regulating T cell receptor activity. | Commun Biol | 2022 | 35017678 | PubTator, text mining | PubMed |
| EZH2 depletion potentiates MYC degradation inhibiting neuroblastoma and small cell carcinoma tumor formation. | Nat Commun | 2022 | 35013218 | PubTator, text mining | PubMed |
| A somatic UBA2 variant preceded ETV6-RUNX1 in the concordant BCP-ALL of monozygotic twins. | Blood Adv | 2022 | 34982829 | PubTator, text mining | PubMed |
| Engineering, decoding and systems-level characterization of chimpanzee cytomegalovirus. | PLoS Pathog | 2022 | 34982803 | PubTator, text mining | PubMed |
| Pathogenesis and virulence of Candida albicans. | Virulence | 2022 | 34964702 | PubTator, text mining | PubMed |
Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)- expressing T cells. | Haematologica | 2022 | 34911282 | PubTator, text mining | PubMed |
| Epigenetic regulation of natural killer cell memory. | Immunol Rev | 2022 | 34908173 | PubTator, text mining | PubMed |
| Enhancing CAR T function with the engineered secretion of C. perfringens neuraminidase. | Mol Ther | 2022 | 34813961 | PubTator, text mining | PubMed |
| Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry. | Leuk Lymphoma | 2022 | 34727819 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/965/papers?page=35